The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index; none of the 124 sources its claims cite is checked for support yet.
Clonal hematopoiesis in human aging and disease
Open accessAbstract
Cryptic signs of aging in our blood: Time is not a friend to our DNA. Aging is associated with an accumulation of somatic mutations in normal dividing cells, including the hematopoietic stem cells (HSCs) that give rise to all blood cells. Certain mutations in HSCs confer a fitness advantage that results in clonal expansions of mutant blood cells that sometimes—but not always—forecast the development of cancer and other age-related diseases. Jaiswal and Ebert review this process of “clonal hematopoiesis,” including the mechanisms by which it arises and the current state of knowledge regarding its effects on human health. Science , this issue p. eaan4673
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
Clonal hematopoiesis, especially CHIP, is common with aging and driven largely by DNMT3A/TET2 mutations; it raises risk of blood cancers, cardiovascular disease, and mortality. Mouse and human data support causal roles in atherosclerosis and inflammation, though mechanisms and broader disease links remain uncertain.
Key findings
- Clonal hematopoiesis is age-related: detectable in <1% of healthy individuals under age 40 but 10–20% of those age 70 or older; in one study, a median of ~18% of blood cells carried the mutations. Nearly two-thirds of clonal hematopoiesis was accounted for by loss-of-function mutations in DNMT3A and TET2, with ASXL1 third most common.
- CHIP was associated with ~10-fold increased relative risk of hematological malignancies; 4% of CHIP carriers developed a blood cancer over 8 years, corresponding to ~0.5% conversion per year. Nested case-control studies found ~3- to 5-fold increased AML risk.
- CHIP was associated with a 30–40% increased mortality risk and increased cardiovascular risk: coronary heart disease and ischemic stroke risk more than doubled, early-onset MI risk was four times higher, and JAK2 mutations conferred ~12-fold higher coronary heart disease risk and ~12-fold venous thrombosis risk.
- Mouse models showed that Tet2 or Dnmt3a loss accelerates atherosclerosis and heart failure, with IL-1B blockade reversing accelerated atherosclerosis; CHIP genes also affect inflammatory pathways including IL6 and IL8.
Methods
- Narrative review; no primary data collection or formal meta-analysis.
- Synthesizes human population and exome sequencing studies, including cohorts of greater than 30,000 persons, nested case-control studies, and mouse models.
- Main analysis is qualitative synthesis of genetic associations, clinical outcomes, and mechanistic experiments.
Limitations
- Stated: mechanisms by which DNMT3A/TET2 and splicing factor mutations drive clonal expansion remain unclear; causality for non-malignant diseases beyond cardiovascular disease is not established, with type 2 diabetes possibly reflecting reverse causation and COPD potentially confounded by smoking.
- Stated: prevalence estimates depend heavily on detection sensitivity, and the biological significance of smaller clones is unknown; clone trajectories vary between people and risk stratification remains incomplete.
- Evident: as a narrative review, it lacks systematic search or quality assessment and provides no new primary data; risk estimates are drawn from heterogeneous studies.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 124 cited sources checked · 0 supported · 0 flagged
In the paper
“As each HSC acquires ~1 exonic mutation per decade of life 3,”
§ Clonal hematopoiesis in human aging and disease > Introduction
What the sources say
- Not checked yetcites [3] Welch JS The origin and evolution of mutations in acute myeloid leukemia. Cell 150, 264– 278, doi: 10.1016/j.cell.2012.06.023 (2012). 22817890 PMC3407563 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIn the paper
“But in the 1990s, studies of non-random X-chromosome inactivation (XCI) in women led to the discovery that clonal hematopoiesis also occurs in individuals without cancer 18.”
§ Clonal hematopoiesis in human aging and disease > A brief history of clonal hematopoiesis
What the sources say
- Not checked yetcites [18] Fey MF Clonality and X-inactivation patterns in hematopoietic cell populations detected by the highly informative M27 beta DNA probe. Blood 83, 931– 938 (1994). 8111064 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesThe paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The surprising result of this experiment of nature was that clonal hematopoiesis largely results from mutations in a very restricted set of genes.”
§ Clonal hematopoiesis in human aging and disease > Clonal hematopoiesis in the genome sequencing era
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesThe paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“This outgrowth, called “clonal hematopoiesis,” is highly prevalent in the elderly population.”
- Also stated in: § Introduction · boosted
“Indeed, numerous studies have now shown that such outgrowths of mutated blood cells, termed “clonal hematopoiesis,” are highly prevalent in the elderly.”
§ Clonal hematopoiesis in human aging and disease > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § Introduction · boosted
In the paper
“Importantly, non-random XCI in blood cells was observed to increase in frequency with age, although the underlying mechanism was unclear 19.”
§ Clonal hematopoiesis in human aging and disease > A brief history of clonal hematopoiesis
What the sources say
- Not checked yetcites [19] Champion KM, Gilbert JG, Asimakopoulos FA, Hinshelwood S & Green AR Clonal haemopoiesis in normal elderly women: implications for the myeloproliferative disorders and myelodysplastic syndromes. British journal of haematology 97, 920– 926 (1997). 9217198 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The third most commonly mutated gene was ASXL1, a chromatin regulator, while mutations in splicing factors (SF3B1, SRSF2, PRPF8, U2AF1) were also frequent.”
§ Clonal hematopoiesis in human aging and disease > Clonal hematopoiesis in the genome sequencing era
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“This was the first demonstration that mutation-driven clonal hematopoiesis occurs in healthy persons 20.”
§ Clonal hematopoiesis in human aging and disease > A brief history of clonal hematopoiesis
What the sources say
- Not checked yetcites [20] Busque L Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nature genetics 44, 1179– 1181, doi: 10.1038/ng.2413 (2012). 23001125 PMC3483435 source
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“Like most cancers, AML generally results from several driver mutations that occur sequentially in the same clone over time 3.”
§ Clonal hematopoiesis in human aging and disease > A brief history of clonal hematopoiesis
What the sources say
- Not checked yetcites [3] Welch JS The origin and evolution of mutations in acute myeloid leukemia. Cell 150, 264– 278, doi: 10.1016/j.cell.2012.06.023 (2012). 22817890 PMC3407563 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesThe paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Mutations in classical oncogenes and tumor suppressors, such as those involved in cellular growth signaling (JAK2, GNAS, GNB1, CBL) and the DNA damage response (TP53, PPM1D), were seen but were not the most common.”
§ Clonal hematopoiesis in human aging and disease > Clonal hematopoiesis in the genome sequencing era
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIn the paper
“The size of these mutant clones was massive; in one study, a median of ~18% of blood cells carried the mutations 28.”
§ Clonal hematopoiesis in human aging and disease > Clonal hematopoiesis in the genome sequencing era
What the sources say
- Not checked yetcites [28] Jaiswal S Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371, 2488– 2498, doi: 10.1056/NEJMoa1408617 (2014). 25426837 PMC4306669 source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes
- It may state two separate claims as one. 31
- Probably not a substantial claim. 18
None of the sources cited for this claim have been checked yet.
In the paper
“An equivalent state is also pervasive in the epithelium of skin 14 and esophagus 15,16, suggesting that somatic mutation-driven clonal expansions may be a characteristic of aging in several tissues.”
§ Clonal hematopoiesis in human aging and disease > Introduction
What the sources say
- Not checked yetcites [14] Martincorena I Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin. Science 348, 880– 886, doi: 10.1126/science.aaa6806 (2015). 25999502 PMC4471149 source
- Not checked yetcites [15] Martincorena I Somatic mutant clones colonize the human esophagus with age. Science 362, 911– 917, doi: 10.1126/science.aau3879 (2018). 30337457 PMC6298579 source
- Not checked yetcites [16] Yokoyama A Age-related remodelling of oesophageal epithelia by mutated cancer drivers. Nature 565, 312– 317, doi: 10.1038/s41586-018-0811-x (2019). 30602793 source
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“by the age of 70 an average person would be expected to harbor up to 1.4 million protein-coding variants, corresponding to an average of 70 mutations per gene, in at least one HSC (Fig. 1).”
§ Clonal hematopoiesis in human aging and disease > Introduction
Load-bearingStrength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“In later studies, DNA sequencing of HSCs from AML patients in remission revealed that stem cells with only a single driver mutation were often present, suggesting that pre-malignant clonal hematopoiesis was a generalizable finding in AML 23–25.”
§ Clonal hematopoiesis in human aging and disease > A brief history of clonal hematopoiesis
What the sources say
- Not checked yetcites [23] Jan M Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Science translational medicine 4, 149ra118, doi: 10.1126/scitranslmed.3004315 (2012). PMC4045621 22932223 source
- Not checked yetcites [24] Shlush LI Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 506, 328– 333, doi: 10.1038/nature13038 (2014). 24522528 PMC4991939 source
- Not checked yetcites [25] Corces-Zimmerman MR, Hong WJ, Weissman IL, Medeiros BC & Majeti R Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci U S A 111, 2548– 2553, doi: 10.1073/pnas.1324297111 (2014). 24550281 PMC3932921 source
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Aging is associated with a steady increase in the number of somatic mutations in virtually all tissues 1–5.”
§ Clonal hematopoiesis in human aging and disease > Introduction
What the sources say
- Not checked yetcites [1] Blokzijl FJ, Tissue-specific mutation accumulation in human adult stem cells during life. Nature 538, 260 (2016). 27698416 PMC5536223 source
- Not checked yetcites [2] Hoang ML, Genome-wide quantification of rare somatic mutations in normal human tissues using massively parallel sequencing. Proc Natl Acad Sci U S A 113, 9846 (2016). 27528664 PMC5024639 source
- Not checked yetcites [3] Welch JS The origin and evolution of mutations in acute myeloid leukemia. Cell 150, 264– 278, doi: 10.1016/j.cell.2012.06.023 (2012). 22817890 PMC3407563 source
- Not checked yetcites [4] Martincorena I & Campbell PJ Somatic mutation in cancer and normal cells. Science 349, 1483– 1489, doi: 10.1126/science.aab4082 (2015). 26404825 source
- Not checked yetcites [5] Yizhak K, RNA sequence analysis reveals macroscopic somatic clonal expansion across normal tissues. Science 364, doi: 10.1126/science.aaw0726 (2019). PMC7350423 31171663 source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Blood cancers such as chronic myeloid leukemia were first demonstrated to be clonal from karyotypic analysis and are the prototypical example of clonal hematopoiesis 17.”
§ Clonal hematopoiesis in human aging and disease > A brief history of clonal hematopoiesis
What the sources say
- Not checked yetcites [17] Rowley JD Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243, 290– 293 (1973). 4126434 source
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Somatic clones were detectable in less than 1% of healthy individuals under age 40, but they increased in frequency with each decade of life.”
§ Clonal hematopoiesis in human aging and disease > Clonal hematopoiesis in the genome sequencing era
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Clonal hematopoiesis provides a glimpse into the process of mutation and selection that likely occurs in all somatic tissues.”
§ Clonal hematopoiesis in human aging and disease > Abstract
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Mouse models carrying loss-of-function mutations in either of these genes clearly show an HSC competitive advantage in vivo as well as a propensity for leukemia when cooperating mutations are present 50–53.”
§ Clonal hematopoiesis in human aging and disease > Mechanisms of clonal expansion
What the sources say
- Not checked yetcites [50] Ko M Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc Natl Acad Sci U S A 108, 14566– 14571, doi: 10.1073/pnas.1112317108 (2011). 21873190 PMC3167529 source
- Not checked yetcites [51] Challen GA Dnmt3a is essential for hematopoietic stem cell differentiation. Nature genetics 44, 23– 31, doi: 10.1038/ng.1009 (2012). PMC3637952 22138693 source
- Not checked yetcites [52] Guryanova OA DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. Nat Med 22, 1488– 1495, doi: 10.1038/nm.4210 (2016). 27841873 PMC5359771 source
- Not checked yetcites [53] Cole CB Haploinsufficiency for DNA methyltransferase 3A predisposes hematopoietic cells to myeloid malignancies. J Clin Invest 127, 3657– 3674, doi: 10.1172/JCI93041 (2017). 28872462 PMC5617681 source
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“While the accumulation of both small and large somatic variants are linked to aging, the underlying biology of the two is generally non-overlapping.”
§ Clonal hematopoiesis in human aging and disease > Clonal hematopoiesis in the genome sequencing era
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“But large structural variation, such as gains or losses of large segments of chromosomes, also increases with age and has clinically meaningful associations 34–36.”
§ Clonal hematopoiesis in human aging and disease > Clonal hematopoiesis in the genome sequencing era
What the sources say
- Not checked yetcites [34] Bonnefond A Association between large detectable clonal mosaicism and type 2 diabetes with vascular complications. Nature genetics 45, 1040– 1043, doi: 10.1038/ng.2700 (2013). 23852171 source
- Not checked yetcites [35] Jacobs KB Detectable clonal mosaicism and its relationship to aging and cancer. Nature genetics 44, 651– 658, doi: 10.1038/ng.2270 (2012). 22561519 PMC3372921 source
- Not checked yetcites [36] Loh PR Insights into clonal haematopoiesis from 8,342 mosaic chromosomal alterations. Nature 559, 350– 355, doi: 10.1038/s41586-018-0321-x (2018). 29995854 PMC6054542 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Stem cells from these mice are able to serially replate in colony forming assays over many generations, whereas wild-type stem cells quickly lose this capacity, suggestive of enhanced self-renewal capacity in the mutant stem cells 54,55.”
§ Clonal hematopoiesis in human aging and disease > Mechanisms of clonal expansion
What the sources say
- Not checked yetcites [54] Moran-Crusio K Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer cell 20, 11– 24, doi: 10.1016/j.ccr.2011.06.001 (2011). 21723200 PMC3194039 source
- Not checked yetcites [55] Celik H Enforced differentiation of Dnmt3a-null bone marrow leads to failure with c-Kit mutations driving leukemic transformation. Blood 125, 619– 628, doi: 10.1182/blood-2014-08-594564 (2015). 25416276 PMC4304107 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“In one study, 4% of CHIP carriers developed a blood cancer over the subsequent 8 years, corresponding to ~0.5% of CHIP cases converting to malignancy per year 28.”
§ Clonal hematopoiesis in human aging and disease > CHIP and hematological malignancy
What the sources say
- Not checked yetcites [28] Jaiswal S Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371, 2488– 2498, doi: 10.1056/NEJMoa1408617 (2014). 25426837 PMC4306669 source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“For comparison, previously described mutations in the blood of healthy persons such as BCR-ABL or BCL2 translocations were usually present in less than 0.01% of cells and were often transient 29,30.”
§ Clonal hematopoiesis in human aging and disease > Clonal hematopoiesis in the genome sequencing era
What the sources say
- Not checked yetcites [29] Biernaux C, Loos M, Sels A, Huez G & Stryckmans P Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 86, 3118– 3122 (1995). 7579406 source
- Not checked yetcites [30] Liu Y, Hernandez AM, Shibata D & Cortopassi GA BCL2 translocation frequency rises with age in humans. Proc Natl Acad Sci U S A 91, 8910– 8914 (1994). 8090743 PMC44716 source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“The PIGA gene is required for the synthesis of glycophosphotidylinositol (GPI) and its loss results in down-regulation of several cell surface proteins that are GPI anchored 60.”
§ Clonal hematopoiesis in human aging and disease > Mechanisms of clonal expansion
What the sources say
- Not checked yetcites [60] Brodsky RA Paroxysmal nocturnal hemoglobinuria. Blood 124, 2804– 2811, doi: 10.1182/blood-2014-02-522128 (2014). 25237200 PMC4215311 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Stochastic processes such as constriction of the stem cell pool with aging may also lead to clonal hematopoiesis in the absence of a known driver mutation.”
§ Clonal hematopoiesis in human aging and disease > Clonal hematopoiesis of indeterminate potential (CHIP)
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“CHIP itself does not denote a malignancy, nor is it associated with clinically significant alterations in blood counts 28,63.”
§ Clonal hematopoiesis in human aging and disease > CHIP and hematological malignancy
What the sources say
- Not checked yetcites [28] Jaiswal S Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371, 2488– 2498, doi: 10.1056/NEJMoa1408617 (2014). 25426837 PMC4306669 source
- Not checked yetcites [63] Buscarlet M DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions. Blood 130, 753– 762, doi: 10.1182/blood-2017-04-777029 (2017). 28655780 source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Loss of some of these proteins may allow for immune escape, thus explaining selection for PIGA-mutated clones.”
§ Clonal hematopoiesis in human aging and disease > Mechanisms of clonal expansion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes? Based: unclearIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“For example, CHIP has been reported to be more common in older men 28 and smokers 27 and less common in Hispanics 28, although these associations are all relatively modest.”
§ Clonal hematopoiesis in human aging and disease > Mechanisms of clonal expansion
What the sources say
- Not checked yetcites [28] Jaiswal S Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371, 2488– 2498, doi: 10.1056/NEJMoa1408617 (2014). 25426837 PMC4306669 source
- Not checked yetcites [27] Genovese G Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 371, 2477– 2487, doi: 10.1056/NEJMoa1409405 (2014). 25426838 PMC4290021 source
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Subsequent studies showed that loss of Tet2 or Dnmt3a led to worsening heart function in a mouse model of congestive heart failure, corroborating the human genetic association 87,88.”
§ Clonal hematopoiesis in human aging and disease > CHIP and non-malignant disease
What the sources say
- Not checked yetcites [87] Sano S CRISPR-Mediated Gene Editing to Assess the Roles of Tet2 and Dnmt3a in Clonal Hematopoiesis and Cardiovascular Disease. Circ Res 123, 335– 341, doi: 10.1161/CIRCRESAHA.118.313225 (2018). 29728415 PMC6054544 source
- Not checked yetcites [88] Sano S Tet2-Mediated Clonal Hematopoiesis Accelerates Heart Failure Through a Mechanism Involving the IL-1beta/NLRP3 Inflammasome. J Am Coll Cardiol 71, 875– 886, doi: 10.1016/j.jacc.2017.12.037 (2018). 29471939 PMC5828038 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These studies indicate that CHIP in the setting of other cancers is likely to be especially pervasive and portends a poor prognosis.”
§ Clonal hematopoiesis in human aging and disease > CHIP and hematological malignancy
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Furthermore, JAK2 mutations prime neutrophils to form neutrophil extracellular traps, leading to thrombosis, which may also contribute to poor cardiovascular outcomes 82.”
§ Clonal hematopoiesis in human aging and disease > CHIP and non-malignant disease
What the sources say
- Not checked yetcites [82] Wolach O Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Science translational medicine 10, doi: 10.1126/scitranslmed.aan8292 (2018). PMC6442466 29643232 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Patients with CHIP also had increased mortality, most often due to progression of their primary malignancy.”
§ Clonal hematopoiesis in human aging and disease > CHIP and hematological malignancy
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“First, tissue architecture constrains the extent of clonal expansion within tissues such as gut or skin epithelium to patches that are rarely larger than a few square millimeters 15, but there is no such spatial restriction on HSCs, which freely admix throughout the bone marrow and body 78.”
§ Clonal hematopoiesis in human aging and disease > CHIP and non-malignant disease
What the sources say
- Not checked yetcites [15] Martincorena I Somatic mutant clones colonize the human esophagus with age. Science 362, 911– 917, doi: 10.1126/science.aau3879 (2018). 30337457 PMC6298579 source
- Not checked yetcites [78] Wright DE, Wagers AJ, Gulati AP, Johnson FL & Weissman IL Physiological migration of hematopoietic stem and progenitor cells. Science 294, 1933– 1936, doi: 10.1126/science.1064081 (2001). 11729320 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Heart function in these studies was also improved with blockade of IL-1B, suggesting that this may be a common pathway for reversing the effects of CHIP in the heart.”
§ Clonal hematopoiesis in human aging and disease > CHIP and non-malignant disease
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“this could represent a case of reverse causation, as hyperglycemia might influence the development or expansion of clones by interfering with TET2 function 90”
§ Clonal hematopoiesis in human aging and disease > CHIP and non-malignant disease
What the sources say
- Not checked yetcites [90] Wu D Glucose-regulated phosphorylation of TET2 by AMPK reveals a pathway linking diabetes to cancer. Nature 559, 637– 641, doi: 10.1038/s41586-018-0350-5 (2018). 30022161 PMC6430198 source
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“In addition, individuals with larger mutant clones had the greatest risk of cardiovascular disease, mirroring the situation for malignancy risk 79.”
§ Clonal hematopoiesis in human aging and disease > CHIP and non-malignant disease
What the sources say
- Not checked yetcites [79] Jaiswal S Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. N Engl J Med 377, 111– 121, doi: 10.1056/NEJMoa1701719 (2017). 28636844 PMC6717509 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“In contrast to tissue-specific cells or epithelia, immune cells such as lymphocytes, granulocytes, and monocytes can migrate to and influence nearly every organ.”
§ Clonal hematopoiesis in human aging and disease > CHIP and non-malignant disease
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✗ Based: failsProbably not a substantial claim. The paper may give no reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Myeloid malignancies were most common, although some people with CHIP did develop lymphoid cancers 27,28.”
§ Clonal hematopoiesis in human aging and disease > CHIP and hematological malignancy
What the sources say
- Not checked yetcites [27] Genovese G Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med 371, 2477– 2487, doi: 10.1056/NEJMoa1409405 (2014). 25426838 PMC4290021 source
- Not checked yetcites [28] Jaiswal S Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371, 2488– 2498, doi: 10.1056/NEJMoa1408617 (2014). 25426837 PMC4306669 source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Mutations in JAK2 have a well-described role in activating STAT transcription factors, which are central to immune response in several cell types involved in atherosclerosis.”
§ Clonal hematopoiesis in human aging and disease > CHIP and non-malignant disease
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
In the paper
“In a separate study (83), individuals with CHIP-associated JAK2 mutations were reported to have a ~12 times greater risk of developing venous thrombosis than those without CHIP, whereas individuals with mutations in other CHIP-associated genes had a doubling of the risk 82.”
§ Clonal hematopoiesis in human aging and disease > CHIP and non-malignant disease
What the sources say
- Not checked yetcites [82] Wolach O Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Science translational medicine 10, doi: 10.1126/scitranslmed.aan8292 (2018). PMC6442466 29643232 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Both groups found that loss of Tet2 in bone marrow cells led to an increase in the size of atherosclerotic lesions in hyperlipidemic mice, an effect that could not be explained by quantitative changes in blood cell parameters of the mutant mice 79,86.”
§ Clonal hematopoiesis in human aging and disease > CHIP and non-malignant disease
What the sources say
- Not checked yetcites [79] Jaiswal S Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. N Engl J Med 377, 111– 121, doi: 10.1056/NEJMoa1701719 (2017). 28636844 PMC6717509 source
- Not checked yetcites [86] Fuster JJ Clonal hematopoiesis associated with Tet2 deficiency accelerates atherosclerosis development in mice. Science, doi: 10.1126/science.aag1381 (2017). PMC5542057 28104796 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“However, CHIP was also strongly linked to smoking in these studies, so the result could be confounded by this association.”
§ Clonal hematopoiesis in human aging and disease > CHIP and non-malignant disease
What the sources say
- Not checked yetcites [37] Zink F Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. Blood 130, 742– 752, doi: 10.1182/blood-2017-02-769869 (2017). 28483762 PMC5553576 source
- Not checked yetcites [63] Buscarlet M DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions. Blood 130, 753– 762, doi: 10.1182/blood-2017-04-777029 (2017). 28655780 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Mechanistically, very little is known about why these specific gene expression changes are seen with loss of Dnmt3a.”
§ Clonal hematopoiesis in human aging and disease > Immune function and CHIP
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Some people have clones that remain stagnant in size for many years, whereas other people have clones that show steady growth 28,33.”
§ Clonal hematopoiesis in human aging and disease > Future outlook
What the sources say
- Not checked yetcites [28] Jaiswal S Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 371, 2488– 2498, doi: 10.1056/NEJMoa1408617 (2014). 25426837 PMC4306669 source
- Not checked yetcites [33] Young AL, Challen GA, Birmann BM & Druley TE Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. Nat Commun 7, 12484, doi: 10.1038/ncomms12484 (2016). 27546487 PMC4996934 source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Understanding the causes and consequences of clonal hematopoiesis may provide a framework to understand this process, and aging, more broadly.”
§ Clonal hematopoiesis in human aging and disease > Future outlook
Tests✓ Asserted: passes✗ Checkable: fails✓ Load-bearing: passes✗ Based: failsProbably not a substantial claim. It may be too vague to check against evidence. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“It is also uncertain why some people have apparent clonal hematopoiesis in the absence of a known driver mutation.”
§ Clonal hematopoiesis in human aging and disease > Future outlook
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“It is associated with blood cancers, cardiovascular disease, and overall mortality.”
§ Clonal hematopoiesis in human aging and disease > Future outlook
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✗ Based: failsProbably not a substantial claim. The paper may give no reason why it holds. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“It is striking that the two most commonly mutated genes in CHIP, DNMT3A and TET2, are opposing enzymes in DNA methylation, yet both lead to convergent phenotypes in stem cell biology and immunity.”
§ Clonal hematopoiesis in human aging and disease > Future outlook
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The mechanisms by which the CHIP-associated mutations cause clonal expansion and enhanced inflammation is also a central unanswered question.”
§ Clonal hematopoiesis in human aging and disease > Future outlook
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
In the paper
“Bone marrow transplant recipients with hematological malignancies who received donor marrow from carriers of CHIP had higher rates of graft-versus-host disease and reduced relapse rates 95.”
§ Clonal hematopoiesis in human aging and disease > Immune function and CHIP
What the sources say
- Not checked yetcites [95] Frick M Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol, JCO2018792184, doi: 10.1200/JCO.2018.79.2184 (2018). 30403573 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The process of mutation and clonal selection is likely to be universal across all organs and tissues.”
§ Clonal hematopoiesis in human aging and disease > Future outlook
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The changes in expression are relatively modest for each gene (~2 to 3-fold increase) but appear to be biologically significant given the number of genes that are dysregulated and the breadth of phenotypes seen in Tet2 knockout mice.”
§ Clonal hematopoiesis in human aging and disease > Immune function and CHIP
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“One possible explanation for this finding is that the donor cells harboring the mutations were capable of mounting stronger immune responses against both normal host tissues and the tumor.”
§ Clonal hematopoiesis in human aging and disease > Immune function and CHIP
What the sources say
- Not checked yetcites [95] Frick M Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol, JCO2018792184, doi: 10.1200/JCO.2018.79.2184 (2018). 30403573 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Furthermore, the interaction of CHIP with other risk factors, such as having type 2 diabetes or elevated serum levels of C-reactive protein, may be synergistic for adverse outcomes.”
§ Clonal hematopoiesis in human aging and disease > Future outlook
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“It is likely that cell extrinsic factors, like the microenvironment, the microbiome, or diet, will play a role.”
§ Clonal hematopoiesis in human aging and disease > Future outlook
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✗ Checkable: fails✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. It may be too vague to check against evidence. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
The authors state this as an assumption.
Given a sufficiently large population, every possible mutation that can occur will occur in some HSCs.
“These studies can be thought of as a natural experiment of saturation mutagenesis in humans, and can be summarized in a simple postulate—given a sufficiently large population, every possible mutation that can occur will occur in some HSCs.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“as CHIP mutations are known to increase the fitness of HSCs and myeloid progenitors5”
From Clonal hematopoiesis is associated with protection from Alzheimer’s disease (2023) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most large-population-based studies define CHIP using a VAF threshold of ≥2%, reflecting the lower limit of reliable detection in standard whole-exome sequencing pipelines [2,32].”
From Clonal Hematopoiesis of Indeterminate Potential as an Emerging Interdisciplinary Risk Factor in Alzheimer’s Disease: Current Evidence and Future Directions (2026) · cites this paper as [32]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The prevalence of CHIP increases sharply with age, creating a significant biological intersection between individuals at risk for CHIP and late-onset AD [9,32].”
From Clonal Hematopoiesis of Indeterminate Potential as an Emerging Interdisciplinary Risk Factor in Alzheimer’s Disease: Current Evidence and Future Directions (2026) · cites this paper as [32]
The cited source says what the claim attributes to it.
In the citing paper
“Examples include the possible links between clonal haematopoiesis and cardiovascular disease54; between mutations in liver disease and insulin resistance55; and between driver mutations in cavernomas and brain haemorrhages49,53,56.”
From Somatic mutation rates scale with lifespan across mammals (2022) · cites this paper as [56]
In the citing paper
“In humans, this manifests itself as ‘clonal haematopoiesis’, where one or a few HSC clones disproportionately contribute to blood production over time48,49.”
From Ageing and rejuvenation of tissue stem cells and their niches (2023) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Venous-thrombosis study is cited as reference 83
MinorThe text identifies reference 83 as a study of venous thrombosis in people with CHIP, but the paper's own reference 83 concerns red blood cell distribution width and risk of death.
“In a separate study (83), individuals with CHIP-associated JAK2 mutations were reported to have a ~12 times greater risk of developing venous thrombosis than those without CHIP”
“83. Patel KV, Ferrucci L, Ershler WB, Longo DL & Guralnik JM Red blood cell distribution width and the risk of death in middle-aged and older adults.”
Citations
Cites
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738 · cited 1×
“If the first mutation to be acquired leads to clonal expansion without malignant transformation, it should be possible to identify a premalignant stage in which only the initiating lesion is present (22).”
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078 · cited 16×
“M. A. Sanders et al., MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML.”
BackgroundInfluentialAge-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841 · cited 9×
“Indeed, some individuals with clonal hematopoiesis have nearly all of their blood cells arising from a single mutated HSC (29).”
BackgroundInfluentialSelf-citationROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291 · cited 1×
“Blood cancers such as chronic myeloid leukemia were first demonstrated to be clonal from karyotypic analysis and are the prototypical example of clonal hematopoiesis (18).”
BackgroundChronic Inflammation (Inflammaging) and Its Potential Contribution to Age-Associated Diseases
Franceschi, C., & Campisi, J. (2014) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glu057 · Cited by 3,891 · cited 1×
“Growing evidence thus supports a role for the commonlymutatedCHIP genes in immune function, and CHIP may underlie some part of the phenomenon termed “inflammaging,” the age-associated increase in systemic inflammation (98).”
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470 · cited 1×
“Activating mutations in JAK2 allow constitutive signaling though growth factor receptors, thus leading to clonal expansion by enhanced proliferation of cells that carry this mutation (46).”
BackgroundTet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine
Ito, S., Shen, L., Dai, Q., Wu, S. C., Collins, L. B., Swenberg, J. A., He, C., & Zhang, Y. (2011) · Science · doi:10.1126/science.1210597 · Cited by 3,451 · cited 1×
“TET2 is one of three enzymes responsible for catalyzing the oxidation of 5-methylcytosine to 5-hydroxymethylcytosine and further intermediates, which can eventually lead to demethylation (49, 50).”
DNA methylation-based biomarkers and the epigenetic clock theory of ageing
Horvath, S., & Raj, K. (2018) · Nature Reviews Genetics · doi:10.1038/s41576-018-0004-3 · Cited by 3,095 · cited 1×
“Like several other welldescribed markers in blood cells, such as red cell distributionwidth (84), DNAmethylation clocks (85), and loss of Y chromosome (86), CHIP is associated with multiple adverse outcomes in epidemiological studies.”
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 1,000
The Role of the Inflammasome in Heart Failure
Wu, J., Dong, E., Zhang, Y., & Xiao, H. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.709703 · Cited by 78
Sheppard, S. E., Campbell, I. M., Harr, M. H., Gold, N. B., Li, D., Bjornsson, H. T., Cohen, J. S., Fahrner, J. A., Fatemi, A. S., Harris, J. R., et al. (2021) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.62124 · Cited by 73
“Another possibility is that these variants in gnomAD are the consequence of clonal hematopoiesis of indeterminate potential as a result of aging (Jaiswal & Ebert, 2019).”
BackgroundKwan, T. T., Oza, A. M., Tinker, A. V., Ray-Coquard, I. L., Oaknin, A., Aghajanian, C. A., Lorusso, D., Colombo, N., Dean, A. P., Weberpals, J. I., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.4664 · Cited by 77
Rauch, P. J., Gopakumar, J., Silver, A. J., Nachun, D. C., Ahmad, H., McConkey, M. E., Nakao, T., Bosse, M. M., Rentz, T., Gonzalez, N. V., et al. (2023) · Nature Cardiovascular Research · doi:10.1038/s44161-023-00326-7 · Cited by 83
“For the 24-week dataset, an analogous analysis was performed with three modifications: (1) filtering parameters were nFeature_RNA > 300 & nFeature_RNA < 4500 & percent.”
MethodSelf-citationSomatic mutations provide important and unique insights into the biology of complex diseases
Ólafsson, S., & Anderson, C. A. (2021) · Trends in Genetics · doi:10.1016/j.tig.2021.06.012 · Cited by 72
Splicing alterations in healthy aging and disease
Angarola, B. L., & Anczuków, O. (2021) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1643 · Cited by 73
“…large-scale genetic studies have revealed the prevalence of cancer-associated clonal SF mutations in blood of individuals without neoplasia, although at a lower frequency than mutations in epigenetic regulators TET2 and DNMT3A (Genovese et al., 2014; Jaiswal & Ebert, 2019; Xie et al., 2014).”
BackgroundChavakis, T., Wielockx, B., & Hajishengallis, G. (2021) · Annual Review of Physiology · doi:10.1146/annurev-physiol-052521-013627 · Cited by 75
Clonal hematopoiesis and non-hematologic disorders
Jaiswal, S. (2020) · Blood · doi:10.1182/blood.2019000989 · Cited by 182
Self-citationClonal Hematopoiesis and Its Impact on Human Health
Ahmad, H., Jahn, N., & Jaiswal, S. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-042921-112347 · Cited by 66
Self-citationAinciburu, M., Ezponda, T., Berastegui, N., Piérola, A. A., Vilas‐Zornoza, A., Martín‐Úriz, P. S., Alignani, D., Lamo-Espinosa, J. M., San-Julián, M., Jiménez, T., et al. (2023) · eLife · doi:10.7554/elife.79363 · Cited by 68
Clonal tracing with somatic epimutations reveals dynamics of blood ageing
Scherer, M., Singh, I., Braun, M. M., Szu‐Tu, C., Sánchez-Sánchez, P., Lindenhofer, D., Jakobsen, N. A., Körber, V., Kardorff, M., Nitsch, L., et al. (2025) · Nature · doi:10.1038/s41586-025-09041-8 · Cited by 81
“6 and 7).”
Fluctuating methylation clocks for cell lineage tracing at high temporal resolution in human tissues
Gabbutt, C., Schenck, R. O., Weisenberger, D. J., Kimberley, C., Berner, A., Househam, J., Lakatos, E., Robertson‐Tessi, M., Martín, I. R., Patel, R., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-021-01109-w · Cited by 63
Clonal hematopoiesis as a model for premalignant changes during aging
Steensma, D. P., & Ebert, B. L. (2019) · Experimental Hematology · doi:10.1016/j.exphem.2019.12.001 · Cited by 65
“One of the most unexpected and interesting developments in the biology of human aging in recent years has been the discovery of the ubiquity of somatic mosaicism in various tissues of older persons [1 − 4].”
Self-citationGiant cell arteritis: reviewing the advancing diagnostics and management
Bilton, E. J., & Mollan, S. P. (2023) · Eye · doi:10.1038/s41433-023-02433-y · Cited by 67
“The incidence of CHIP correlates with age, and it is associated with increased levels of CRP and other classic systemic inflammatory markers [33, 34].”
BackgroundAccelerated Vascular Aging in Chronic Kidney Disease: The Potential for Novel Therapies
Hobson, S., Arefin, S., Witasp, A., Hernandez, L. N., Kublickiene, K. R., Shiels, P. G., & Stenvinkel, P. (2023) · Circulation Research · doi:10.1161/circresaha.122.321751 · Cited by 64
Immunometabolism in heart failure
Andreadou, I., Ghigo, A., Nikolaou, P., Świrski, F. K., Thackeray, J. T., Heusch, G., & Vilahur, G. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01165-8 · Cited by 76
“Additionally, HSP cells tend to accumulate somatic mutations, some of which confer a survival advantage, resulting in clonal outgrowth, a process referred to as clonal haematopoiesis 151,152 .”
Clonal Hematopoiesis Before, During, and After Human Spaceflight
Mencia-Trinchant, N., MacKay, M. J., Chin, C. R., Afshinnekoo, E., Foox, J., Meydan, C., Butler, D., Mozsary, C., Vernice, N. A., Darby, C. A., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108458 · Cited by 62
“These changes can then be examined relative to published CH guidelines (Bolton et al., 2019a; Jaiswal and Ebert, 2019), other CH data from emerging clinical and control cohorts (Busque et al.”
ResultHajishengallis, G., Li, X., Divaris, K., & Chavakis, T. (2022) · Periodontology 2000 · doi:10.1111/prd.12421 · Cited by 70
Multiscale footprints reveal the organization of cis-regulatory elements
Yan, H., Horlbeck, M. A., Zhang, R., Ma, S., Shrestha, R., Kartha, V. K., Duarte, F. M., Hock, C., Savage, R. E., Labade, A. S., et al. (2025) · Nature · doi:10.1038/s41586-024-08443-4 · Cited by 93
“Biological ageing is a multifactorial process that affects the physiology of a broad range of tissues, including marked changes to function and proliferation of HSCs 35,36 .”
Masselli, E., Pozzi, G., Gobbi, G., Merighi, S., Gessi, S., Vitale, M., & Carubbi, C. (2020) · Cells · doi:10.3390/cells9092136 · Cited by 63
Malignant JAK-signaling: at the interface of inflammation and malignant transformation
Perner, F., Pahl, H. L., Zeiser, R., & Heidel, F. H. (2025) · Leukemia · doi:10.1038/s41375-025-02569-8 · Cited by 71
“Seminal studies have demonstrated that individuals with clonal hematopoiesis (CHIP) had an increased risk of coronary heart disease and ischemic stroke [4, 264, 265].”
In utero origin of myelofibrosis presenting in adult monozygotic twins
Sousos, N., Leathlobhair, M. N., Karali, C. S., Louka, E., Bienz, N., Royston, D. J., Clark, S., Hamblin, A. D., Howard, K., Mathews, V., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01793-4 · Cited by 60
Jahn, E., Saadati, M., Fenaux, P., Gobbi, M., Roboz, G. J., Bullinger, L., Lutsik, P., Riedel, A., Plass, C., Jahn, N., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01999-6 · Cited by 62
Functional diversity of cardiac macrophages in health and disease
Yang, S. H., Penna, V. R., & Lavine, K. J. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01109-8 · Cited by 67
“However, CHIP also increases the risk of CVD and cardiovascular-related mortality 94,95 .”
Rando, T. A., Brunet, A., & Goodell, M. A. (2025) · Cell stem cell · doi:10.1016/j.stem.2025.06.004 · Cited by 68
“43 Adult neurogenesis is maintained by symmetric self-renewal and differentiation.”
Cremer, S., Kirschbaum, K., Berkowitsch, A., John, D., Kiefer, K. C., Dorsheimer, L., Wagner, J. U. G., Rasper, T., Abou‐El‐Ardat, K., Aßmus, B., et al. (2020) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.120.003003 · Cited by 61
Spontaneous and inherited TP53 genetic alterations
Levine, A. J. (2021) · Oncogene · doi:10.1038/s41388-021-01991-3 · Cited by 67
“Although these prevalence estimates are dynamically altered based on variable mutation classifications and highly impacted by some specific controvertible spontaneous TP53 mutations, the databases employed could introduce other possible biases, such as CHIP, or enrichment of mutations potentially associated with lower…”
BackgroundMosaic loss of chromosome Y promotes leukemogenesis and clonal hematopoiesis
Zhang, Q., Zhao, L., Yang, Y., Li, S., Liu, Y., & Chen, C. (2022) · JCI Insight · doi:10.1172/jci.insight.153768 · Cited by 60
“Clonal hematopoiesis (CH) is a common aging-related hematopoietic abnormality in which a single hematopoietic stem or progenitor cell gives rise to a substantial proportion of peripheral blood cells or bone marrow cells (hematopoietic stem and progenitor cells, HSPCs) (11).”
BackgroundBöhme, M., Desch, S., Rosołowski, M., Scholz, M. R., Krohn, K., Buttner, P. G., Cross, M. A., Kirchberg, J., Rommel, K., Pöss, J., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.08.740 · Cited by 63
The evolution of hematopoietic cells under cancer therapy
Pich, O., Cortés‐Bullich, A., Muiños, F., Pratcorona, M., González-Pérez, A., & López-Bigas, N. (2021) · Nature Communications · doi:10.1038/s41467-021-24858-3 · Cited by 60
Inflammation, Aging and Hematopoiesis: A Complex Relationship
Bousounis, P., Bergo, V., & Trompouki, E. (2021) · Cells · doi:10.3390/cells10061386 · Cited by 64
Cardio-Oncology: A Myriad of Relationships Between Cardiovascular Disease and Cancer
Wang, Y., Wang, Y., Han, X., Sun, J. H., Li, C., Adhikari, B. K., Zhang, J., Miao, X., & Chen, Z. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.727487 · Cited by 63
“CHIP increases the risk of atherogenesis and accelerates atherosclerosis and chronic cardiac insufficiency, leading to a poor prognosis for such patients (20).”
BackgroundClonal Hematopoiesis: From Mechanisms to Clinical Intervention
Köhnke, T., & Majeti, R. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0901 · Cited by 63
Promises and pitfalls of multi-cancer early detection using liquid biopsy tests
Wan, J. C. M., Sasieni, P. D., & Rosenfeld, N. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01033-x · Cited by 69
“Even with error suppression, clonal haematopoiesis of indeterminate potential (CHIP), which is a universal mechanism of ageing in which mutations accumulate in blood cells or bone marrow cells 43,60,61 , presents an additional challenge.”
Inflammatory Cytokines Shape an Altered Immune Response During Myeloid Malignancies
Camacho, V., Kuznetsova, V., & Welner, R. S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.772408 · Cited by 60
Clonal hematopoiesis in sickle cell disease
Liggett, L. A., Cato, L. D., Weinstock, J. S., Zhang, Y., Nouraie, M. S., Gladwin, M. T., Garrett, M. E., Ashley‐Koch, A. E., Telen, M. J., Custer, B., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci156060 · Cited by 61
“However, the clinical implications of small clones in predisposing to myeloid malignancies is unknown and existing literature suggests that only larger clones with VAFs > 10% have prognostic impact [8, 9, 11, 10, 11].”
Somatic and Germline Variants and Coronary Heart Disease in a Chinese Population
Zhao, K., Shen, X., Liu, H., Lin, Z., Li, J., Chen, S., Liu, F., Huang, K., Cao, J., Liu, X., et al. (2024) · JAMA Cardiology · doi:10.1001/jamacardio.2023.5095 · Cited by 59
Anemia and Its Connections to Inflammation in Older Adults: A Review
Wacka, E., Nicikowski, J., Jarmużek, P., & Zembroń-Łacny, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13072049 · Cited by 64
“With age, somatic mutations also affect all cells involved in hematopoiesis, resulting in clonal hematopoiesis [33].”
BackgroundCancer treatment monitoring using cell-free DNA fragmentomes
Erve, I. V. '., Alipanahi, B., Lumbard, K., Skidmore, Z., Rinaldi, L., Millberg, L. K., Carey, J., Chesnick, B., Cristiano, S., Portwood, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53017-7 · Cited by 52
“9, 10).”
Somatic Mutations in Cardiovascular Disease
Heimlich, J. B., & Bick, A. G. (2022) · Circulation Research · doi:10.1161/circresaha.121.319809 · Cited by 56
Patnaik, M. M., & Tefferi, A. (2021) · American Journal of Hematology · doi:10.1002/ajh.26090 · Cited by 57
“Clonal hematopoiesis is associated with an increased risk of developing myeloid neoplasms, as well as an increased all-cause mortality, largely due to cardiovascular disease.(100) The presence of CH in the”
BackgroundCirculating Tumor DNA: An Emerging Tool in Gastrointestinal Cancers
Alese, O. B., Cook, N., Franco, A. O., Ulanja, M. B., Tan, L., & Tie, J. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_349143 · Cited by 54
Clonal haematopoiesis of indeterminate potential and atrial fibrillation: an east Asian cohort study
Ahn, H., An, H. Y., Ryu, G., Lim, J., Sun, C.-H., Song, H., Choi, S., Lee, H., Maurer, T. M., Nachun, D. C., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehad869 · Cited by 60
Self-citationDevelopmental and temporal characteristics of clonal sperm mosaicism
Yang, X., Breuss, M. W., Xu, X., Antaki, D., James, K. N., Stanley, V., Ball, L., George, R. D., Wirth, S. A., Cao, B., et al. (2021) · Cell · doi:10.1016/j.cell.2021.07.024 · Cited by 55
Inflammation and Aging of Hematopoietic Stem Cells in Their Niche
Yang, D., & de Haan, G. (2021) · Cells · doi:10.3390/cells10081849 · Cited by 55
Impact of Acute and Chronic Psychosocial Stress on Vascular Inflammation
Hinterdobler, J., Schunkert, H., Kessler, T., & Sager, H. B. (2021) · Antioxidants and Redox Signaling · doi:10.1089/ars.2021.0153 · Cited by 56
“Clonal hematopoiesis, the process in which increasing numbers of white blood cells derive from one single clone due to specific somatic mutations in hematopoietic stem cells (64), has recently been identified as a pathophysiological mechanism that links aging with atherosclerosis (65).”
BackgroundModern Concepts in Cardiovascular Disease: Inflamm-Aging
Puspitasari, Y. M., Ministrini, S., Schwarz, L., Karch, C., Liberale, L., & Camici, G. G. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.882211 · Cited by 57
Clonal Hematopoiesis of Indeterminate Potential in Patients with Solid Tumor Malignancies
Marshall, C. H., Gondek, L. P., Luo, J., & Antonarakis, E. S. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0985 · Cited by 54
Lazar, N. H., Çelik, S., Chen, L., Fay, M. M., Irish, J. C., Jensen, J., Tillinghast, C. A., Urbanik, J., Bone, W. P., Roberts, G. H. L., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01758-y · Cited by 52
Epigenetic regulation of hematopoietic stem cell fate
Meng, Y., & Nerlov, C. (2024) · Trends in Cell Biology · doi:10.1016/j.tcb.2024.08.005 · Cited by 53
“Consistent with the observations in genetically modified mice, CH is highly associated with mutations in DNMT3A and TET2 [70, 71], which enhance HSC fitness, as discussed above.”
Hematopoietic Stem Cells and the Immune System in Development and Aging
Shevyrev, D., Tereshchenko, V., Berezina, T. N., & Александрович, Р. С. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065862 · Cited by 58
The complex interplay between aging and cancer
Trastus, L. A., & di Fagagna, F. D. (2025) · Nature Aging · doi:10.1038/s43587-025-00827-z · Cited by 56
“CHIP is considered a premalignant state, associated with up to a tenfold higher risk of developing hematopoietic malignancies, cardiovascular diseases and all-cause mortality 36 .”
InfluentialAguilar-Navarro, A. G., Meza-León, B., Gratzinger, D. A., Juárez-Aguilar, F. G., Chang, Q., Ornatsky, O., Tsui, H., Gómez, R. E., Hernández-Ramírez, A., Xie, S. Z.-J., et al. (2020) · Stem Cell Reports · doi:10.1016/j.stemcr.2020.06.011 · Cited by 47
“The frequency of somatic mutations and clonal hematopoiesis, known risk factors of hematological cancer, increase dramatically with aging (Jaiswal and Ebert, 2019; Steensma and Ebert, 2020).”
BackgroundCancer and Cardiovascular Disease
Alhuneafat, L., Guha, A., Blaes, A. H., & Konety, S. (2025) · JACC CardioOncology · doi:10.1016/j.jaccao.2025.07.001 · Cited by 55
How I diagnose and treat chronic myelomonocytic leukemia
Patnaik, M. M. (2022) · Haematologica · doi:10.3324/haematol.2021.279500 · Cited by 50
Cost-Effective and Scalable Clonal Hematopoiesis Assay Provides Insight into Clonal Dynamics
Mack, T., Vlasschaert, C., von Beck, K., Silver, A. J., Heimlich, J. B., Poisner, H. M., Condon, H. R., Ulloa, J., Sochacki, A. L., Spaulding, T. P., et al. (2024) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2024.03.007 · Cited by 47
Central Nervous System Macrophages in Health and Disease
Hove, H. V., Feo, D. D., Greter, M., & Becher, B. (2025) · Annual Review of Immunology · doi:10.1146/annurev-immunol-082423-041334 · Cited by 53
Common Sources of Inflammation and Their Impact on Hematopoietic Stem Cell Biology
Hormaechea‐Agulla, D., Le, D. T., & King, K. Y. (2020) · Current Stem Cell Reports · doi:10.1007/s40778-020-00177-z · Cited by 48
Functional Consequences of Mutations in Myeloproliferative Neoplasms
Constantinescu, S. N., Vainchenker, W., Levy, G., & Papadopoulos, N. (2021) · HemaSphere · doi:10.1097/hs9.0000000000000578 · Cited by 51
Ogrodnik, M. B., & Gladyshev, V. N. (2023) · Nature Aging · doi:10.1038/s43587-023-00447-5 · Cited by 46
“When it comes to stem cells, there is evidence that their adaptations provide an advantage during aging-induced clonal selection in tissues such as the skin 98 , bone marrow 99 and muscle 100 .”
Gurnari, C., Pascale, M. R., Vitale, A., Diral, E., Tomelleri, A., Galossi, E., Falconi, G., Bruno, A., Crisafulli, F., Frassi, M., et al. (2023) · American Journal of Hematology · doi:10.1002/ajh.27169 · Cited by 47
Clonal haematopoiesis in cardiovascular disease: prognostic role and novel therapeutic target
Schuermans, A., & Honigberg, M. C. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01148-9 · Cited by 52
Castiglione, M. A., Jiang, Y., Mazzeo, C., Lee, S., Chen, J., Kaushansky, K., Yin, W., Lin, R. Z., Zheng, H., & Zhan, H. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15095 · Cited by 45
The rate and nature of mitochondrial DNA mutations in human pedigrees
Árnadóttir, E. R., Moore, K. H. S., Guðmundsdóttir, V. B., Ebenesersdóttir, S. S., Guity, K., Jónsson, H., Stefánsson, K., & Helgason, A. (2024) · Cell · doi:10.1016/j.cell.2024.05.022 · Cited by 52
Base editor scanning charts the DNMT3A activity landscape
Lue, N. Z., Garcia, E. M., Ngan, K. C.-H., Lee, C., Doench, J. G., & Liau, B. B. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-01167-4 · Cited by 47
“Based on this, sgRNAs were placed in one of 7 mutually exclusive classes, listed in order of assignment priority: (1) nonsense; (2) splice site; (3) missense; (4) silent; (5) exon, no predicted edits (no C within window); (6) intron/UTR; (7) intron/UTR, no predicted edits.”
BackgroundCHIP‐associated mutant ASXL1 in blood cells promotes solid tumor progression
Liu, X., Sato, N., Shimosato, Y., Wang, T., Denda, T., Chang, Y., Yabushita, T., Fujino, T., Asada, S., Tanaka, Y., et al. (2022) · Cancer Science · doi:10.1111/cas.15294 · Cited by 42
T cell aging as a risk factor for autoimmunity
Liu, Q., Zheng, Y., Goronzy, J. J., & Weyand, C. M. (2022) · Journal of Autoimmunity · doi:10.1016/j.jaut.2022.102947 · Cited by 48
Shared and distinct genetic etiologies for different types of clonal hematopoiesis
Brown, D. W., Cato, L. D., Zhao, Y., Nandakumar, S. K., Bao, E. L., Gardner, E. J., Hubbard, A. K., DePaulis, A., Rehling, T., Song, L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41315-5 · Cited by 47
“7a) with 439 individuals (6.0% of individuals with CHIP, 6.3% of individuals with autosomal mCAs) carrying both (Supplementary Data 3).”
InfluentialPriorities in Cardio-Oncology Basic and Translational Science
Salloum, F. N., Tocchetti, C. G., Ameri, P., Ardehali, H., Asnani, A. H., de Boer, R. A., Burridge, P. W., Cabrera, J. Á., de Castro, J., Córdoba, R., et al. (2023) · JACC CardioOncology · doi:10.1016/j.jaccao.2023.08.003 · Cited by 46
Somatic mutation as an explanation for epigenetic aging
Koch, Z., Li, A., Evans, D. S., Cummings, S. R., & Ideker, T. (2025) · Nature Aging · doi:10.1038/s43587-024-00794-x · Cited by 48
“5 and 7), the relevance of these findings to normative aging should be further examined in larger datasets of normal individuals and tissues by, for example, applying mutational clocks to independent datasets.”
What To Tell Your Patient With Clonal Hematopoiesis And Why: Insights From Two Specialized Clinics
Steensma, D. P., & Bolton, K. L. (2020) · Blood · doi:10.1182/blood.2019004291 · Cited by 45
The Dynamics of Somatic Mutagenesis During Life in Humans
Manders, F., van Boxtel, R., & Middelkamp, S. (2021) · Frontiers in Aging · doi:10.3389/fragi.2021.802407 · Cited by 48
“Somatic mutations can also lead to non-cancerous, but potentially harmful clonal outgrowth, with clones sometimes replacing entire tissues, for example in clonal hematopoiesis (Jaiswal and Ebert, 2019; Kakiuchi and Ogawa, 2021; Mustjoki and Young, 2021).”
BackgroundYu, K., Deuitch, N. T., Merguerian, M., Cunningham, L., Davis, J., Bresciani, E., Diemer, J. L., Andrews, E. T., Young, A., Donovan, F. X., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023011165 · Cited by 42
“10,11 CH increases with age.”
BackgroundWu, Q., Zhang, W., Lu, Y., Li, H., Yang, Y., Geng, F., Liu, J., Li, L., Pan, Y., & Li, C. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111558 · Cited by 47
Modeling and targeting of erythroleukemia by hematopoietic genome editing
Iacobucci, I., Qu, C., Varotto, E., Janke, L. J., Xu, Y., Seth, A., Shelat, A. A., Friske, J. D., Fukano, R., Yu, J., et al. (2021) · Blood · doi:10.1182/blood.2020009103 · Cited by 44
Self-citationLi, L., Kim, J., Lü, W., Williams, D. M., Kim, J., Cope, L., Rampal, R. K., Koche, R. P., Xian, L., Luo, L., et al. (2022) · Blood · doi:10.1182/blood.2021013925 · Cited by 44
Lin, S., Brown, D. W., Rose, B., Day, F. R., Lee, O. W., Khan, S. M., Hislop, J., Chanock, S. J., Perry, J. R. B., & Machiela, M. J. (2021) · Cell & Bioscience · doi:10.1186/s13578-021-00651-z · Cited by 38
“, somatic SNVs) [16, 21, 22], to very large structural mosaic chromosomal alterations (mCAs) [20, 23, 28, 29, 34, 37, 42, 46].”
BackgroundMolinaro, R., Sellar, R. S., Vromman, A., Sausen, G., Folco, E. J. E., Sukhova, G. K., McConke, M. E., Corbo, C., Ebert, B. L., & Libby, P. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132184 · Cited by 44
Self-citationGenomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes
Patnaik, M. M., & Lasho, T. L. (2020) · Hematology · doi:10.1182/hematology.2020000130 · Cited by 42
NPM1-Mutated Myeloid Neoplasms with <20% Blasts: A Really Distinct Clinico-Pathologic Entity?
Forghieri, F., Nasillo, V., Paolini, A., Bettelli, F., Pioli, V., Giusti, D., Gilioli, A., Colasante, C., Acquaviva, G., Riva, G., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238975 · Cited by 42
“Although relevant to investigate distinct preleukemic Npm1-mutated populations, it should be noted that these multistep leukemogenesis mouse models are hardly reproducible in humans, where NPM1 mutations are not associated with clonal hematopoiesis of indeterminate potential (CHIP) and are overall infrequently documen…”
BackgroundInfluentialKiefer, K. C., Cremer, S., Pardali, E., Aßmus, B., Abou‐El‐Ardat, K., Kirschbaum, K., Dorsheimer, L., Rasper, T., Berkowitsch, A., Serve, H. L., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13297 · Cited by 46
Clonal Hematopoiesis, Inflammation, and Hematologic Malignancy
Kanagal‐Shamanna, R., Beck, D. B., & Calvo, K. R. (2023) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-051222-122724 · Cited by 46
Morganti, S., Gibson, C. J., Jin, Q., Santos, K., Patel, A., Wilson, A., Merrill, M. S., Vincuilla, J., Stokes, S., Lipsyc-Sharf, M. D., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.01071 · Cited by 41
Immunometabolic control of hematopoiesis
Hajishengallis, G., Li, X., & Chavakis, T. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100923 · Cited by 43
Epigenetic modulators provide a path to understanding disease and therapeutic opportunityPreprint
Honer, M. A., Ferman, B. I., Gray, Z. H., Bondarenko, E. A., & Whetstine, J. R. (2024) · Genes & Development · doi:10.1101/gad.351444.123 · Cited by 44
“…turn pathogenesis, which has revealed biomarkers and novel therapeutic targets in order to combat a host of diseases (Dawson and Kouzar-ides 2012; Rando and Chang 2012; Sen et al. 2016; Dobson et al. 2018; Cavalli and Heard 2019; Jaiswal and Ebert 2019; Alonso-Curbelo et al. 2021; Wu et al. 2024).”
BackgroundAge acquired skewed X chromosome inactivation is associated with adverse health outcomes in humans
Roberts, A. L., Morea, A., Amar, A., Zito, A., Moustafa, J. S. E.-S., Tomlinson, M., Bowyer, R. C. E., Zhang, X., Christiansen, C., Costeira, R., et al. (2022) · eLife · doi:10.7554/elife.78263 · Cited by 44
The Role of Inflammation in the Initiation and Progression of Myeloid Neoplasms
Balandrán, J. C., Lasry, A., & Aifantis, I. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-22-0176 · Cited by 44
The coming of age of liquid biopsy in neuro-oncology
Berzero, G., Pieri, V., Mortini, P., Filippi, M., & Finocchiaro, G. (2023) · Brain · doi:10.1093/brain/awad195 · Cited by 41
“87,88 They mainly include mutations in epigenetic modulators ( DNMT3A , TET2 and ASXL ), and in genes often altered in solid ( KRAS , GNAS , NRAS and PIK3CA ) and haematological tumours ( JAK2 , PPM1D , TP53 , SF3B1 , SRSF2 , IDH1 and IDH2 ).”
BackgroundClonal Hematopoiesis of Indeterminate Potential From a Heart Failure Specialist's Point of View
Sikking, M. A., Stroeks, S. L. V. M., Waring, O. J., Henkens, M. T. H. M., Riksen, N. P., Hoischen, A., Heymans, S. R. B., & Verdonschot, J. A. J. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.123.030603 · Cited by 42
Stem-Cell Aging and Pathways to Precancer Evolution
Jamieson, C. H. M., & Weissman, I. L. (2023) · New England Journal of Medicine · doi:10.1056/nejmra2304431 · Cited by 39
Defining precancer: a grand challenge for the cancer community
Faupel‐Badger, J. M., Kohaar, I., Bahl, M., Chan, A. T., Campbell, J. D., Li, J., Marzo, A. M. D., Maitra, A., Merrick, D. T., Hawk, E. T., et al. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00744-0 · Cited by 46
Clonal dynamics and somatic evolution of haematopoiesis in mouse
Kapadia, C. D., Williams, N., Dawson, K. J., Watson, C. J., Yousefzadeh, M. J., Le, D. T., Nyamondo, K., Kodavali, S., Cagan, A., Waldvogel, S. M., et al. (2025) · Nature · doi:10.1038/s41586-025-08625-8 · Cited by 48
“Clonal expansions harboured mutations in Dnmt3a and Tet2 , genes frequently mutated in human clonal haematopoiesis, but also Bcor and Bcorl1 , observed in humans following bone marrow immune insult 7,8 .”
Immunity and inflammation in cardiovascular disorders
Boyalla, V., Gallego-Colón, E., & Spartalis, Μ. (2023) · BMC Cardiovascular Disorders · doi:10.1186/s12872-023-03185-z · Cited by 41
“The pivotal role of innate immunity, especially macrophages, is shown in a recent study showing that a clonal population of granulocytes carrying driver mutation related to haematopoiesis can cause tissue inflammation leading to atherosclerotic diseases [5].”
BackgroundUrbán, V. S., Ceglédi, A., & Mikala, G. (2022) · GeroScience · doi:10.1007/s11357-022-00698-x · Cited by 43
Giannakopoulou, E., Lehander, M., Culleton, S. V., Yang, W., Li, Y., Kärpänen, T., Yoshizato, T., Rustad, E. H., Nielsen, M. M., Bollineni, R. C., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00642-8 · Cited by 41
“In two additional patients, it was only preceded by a recurrent SRSF2 and TET2 mutation, known to occur in normal individuals with clonal hematopoiesis (CH) and requiring additional driver mutations to transform to AML 44 .”
BackgroundLiu, W., Hardaway, B. D., Kim, E., Pauli, J., Wettich, J. L., Yalçınkaya, M., Hsu, C.-C., Xiao, T., Reilly, M. P., Tabas, I. A., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci182939 · Cited by 37
“This condition results from somatic mutations in leukemogenic genes, providing a survival advantage to hematopoietic stem cells and causing the clonal expansion of blood cells (9, 10).”
Hammond, C. A., Wu, S. W., Wang, F., MacAldaz, M. E., & Eaves, C. J. (2023) · Blood · doi:10.1182/blood.2022017174 · Cited by 36
Stem Cell DNA Damage and Genome Mutation in the Context of Aging and Cancer InitiationPreprint
Zouabi, L. A., & Bardin, A. J. (2020) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a036210 · Cited by 39
Meaker, G. A., & Wilkinson, A. C. (2023) · Experimental Hematology · doi:10.1016/j.exphem.2023.12.001 · Cited by 38
Advances in Nonresponsive and Refractory Celiac Disease
Malamut, G., Soderquist, C. R., Bhagat, G., & Cerf–Bensussan, N. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.02.048 · Cited by 43
Metadata
- Authors
- Jaiswal, S., & Ebert, B. L.
- Affiliations
- Stanford Medicine (US)
- Broad Institute (US)
- Corresponding author
- Jaiswal, Siddhartha
- Ebert, Benjamin L.
- Venue
- Science
- Published
- 2019-11
- Volume
- 366
- Issue
- 6465
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC8050831
- OpenAlex
- W2982291252
- Semantic Scholar
- 6d1a7a80dacac969118008d44a082733bff68245
- Cited by
- 1,156
- References
- 98
- Citations by year
- 2026: 173 · 2025: 222 · 2024: 206 · 2023: 169 · 2022: 164 · 2021: 136 · 2020: 83 · 2019: 3
- FWCI
- 15.36
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- The Japanese Society of Hematology
- Funders
- National Institutes of Health (P01CA066996, P50CA206963, R01HL082945)
- Burroughs Wellcome Fund
- Edward P. Evans Foundation
- Ludwig Institute for Cancer Research
- Fondation Leducq
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- clonal hematopoiesis, somatic mutations, aging, hematopoietic stem cells, cancer risk, immune function
- MeSH terms
- Aged, Aging, Animals, Cardiovascular Diseases, Clone Cells, Hematopoiesis, Hematopoietic Stem Cells, Humans, Mutation, Precancerous Conditions, Hematologic Neoplasms, Clonal Evolution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review